Arvinas Dirección

Dirección controles de criterios 2/4

El CEO de Arvinas' es John Houston , nombrado en Sep 2017, tiene una permanencia de 6.58 años. compensación anual total es $7.63M, compuesta por 8.6% salario y 91.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.27% de las acciones de la empresa, por valor de $27.36M. La antigüedad media del equipo directivo y de la junta directiva es de 1.7 años y 4.5 años, respectivamente.

Información clave

John Houston

Chief Executive Officer (CEO)

US$7.6m

Compensación total

Porcentaje del salario del CEO	8.6%
Permanencia del CEO	6.7yrs
Participación del CEO	1.3%
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	4.6yrs

Actualizaciones recientes de la dirección

Recent updates

Arvinas: Behind The Huge Rally

Mar 03

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Feb 25

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Aug 19

Arvinas: Still Holding, Just Not Buying More

May 23

Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma

Feb 07

Arvinas: 2022 Is Full Of Catalysts For This Protein Degrader Pioneer

Nov 19

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de John Houston en comparación con los beneficios de Arvinas?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$355m
Dec 31 2023	US$8m	US$658k	-US$367m
Sep 30 2023	n/a	n/a	-US$295m
Jun 30 2023	n/a	n/a	-US$298m
Mar 31 2023	n/a	n/a	-US$301m
Dec 31 2022	US$10m	US$632k	-US$282m
Sep 30 2022	n/a	n/a	-US$253m
Jun 30 2022	n/a	n/a	-US$233m
Mar 31 2022	n/a	n/a	-US$213m
Dec 31 2021	US$13m	US$584k	-US$191m
Sep 30 2021	n/a	n/a	-US$180m
Jun 30 2021	n/a	n/a	-US$164m
Mar 31 2021	n/a	n/a	-US$139m
Dec 31 2020	US$8m	US$564k	-US$119m
Sep 30 2020	n/a	n/a	-US$99m
Jun 30 2020	n/a	n/a	-US$86m
Mar 31 2020	n/a	n/a	-US$78m
Dec 31 2019	US$5m	US$528k	-US$70m
Sep 30 2019	n/a	n/a	-US$65m
Jun 30 2019	n/a	n/a	-US$173m
Mar 31 2019	n/a	n/a	-US$179m
Dec 31 2018	US$6m	US$428k	-US$240m
Sep 30 2018	n/a	n/a	-US$233m
Jun 30 2018	n/a	n/a	-US$114m
Mar 31 2018	n/a	n/a	-US$98m
Dec 31 2017	US$954k	US$371k	-US$29m

Compensación vs. Mercado: La compensación total de John($USD7.63M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.61M).

Compensación vs. Ingresos: La compensación de John ha sido consistente con los resultados de la empresa en el último año.

CEO

John Houston (63 yo)

6.7yrs

Permanencia

US$7,627,032

Compensación

Dr. John G. Houston, Ph.D. serves as Independent Director at NextCure, Inc. since September 10, 2020. He has been President, Chief Executive Officer and Director of Arvinas, Inc. since September 20, 2017 a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
John Houston	Chairperson	6.7yrs	US$7.63m	1.27% $ 27.3m
Ian Taylor	Chief Scientific Officer	5.2yrs	US$2.73m	0.14% $ 3.0m
David Loomis	VP & Chief Accounting Officer	1.4yrs	sin datos	sin datos
Jeff Boyle	Vice President of Investor Relations	3.3yrs	sin datos	sin datos
Jared Freedberg	General Counsel & Corporate Secretary	less than a year	sin datos	sin datos
Steve Weiss	Senior VP & Chief Human Resources Officer	no data	sin datos	sin datos
John Grosso	Senior Vice President of R&D Technical Operations	no data	sin datos	sin datos
Randy Teel	Chief Business Officer	less than a year	sin datos	0.017% $ 358.6k
Angela Cacace	Senior Vice President of Neuroscience & Platform Biology	no data	sin datos	sin datos
John Northcott	Chief Commercial Officer	1.8yrs	sin datos	sin datos
Lisa Sinclair	Senior Vice President of Corporate Operations	1.8yrs	sin datos	sin datos
Paul McInulty	Senior Vice President of Regulatory Affairs	1.6yrs	sin datos	sin datos

1.8yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ARVN no se considera experimentado ( 1.7 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
John Houston	Chairperson	6.7yrs	US$7.63m	1.27% $ 27.3m
Wendy Dixon	Independent Director	3.9yrs	US$425.40k	0.0073% $ 157.9k
Edward Kennedy	Independent Director	5.8yrs	US$422.69k	0.062% $ 1.3m
Lillian Siu	Member of Scientific Advisory Board	4.6yrs	sin datos	sin datos
Leslie Norwalk	Independent Director	4.8yrs	US$424.99k	0% $ 0
Briggs W. Morrison	Lead Independent Director	5.9yrs	US$441.76k	0.029% $ 630.6k
Laurie Smaldone Alsup	Independent Director	4.5yrs	US$430.30k	0% $ 0
Adam Boxer	Member of Scientific Advisory Board	4.6yrs	sin datos	sin datos
Lennart Mucke	Member of Scientific Advisory Board	4.6yrs	sin datos	sin datos
Bradley Hyman	Member of Scientific Advisory Board	2.2yrs	sin datos	sin datos
Benjamin Neel	Member of Scientific Advisory Board	4.6yrs	sin datos	sin datos
Linda Bain	Independent Director	3.9yrs	US$434.99k	0% $ 0

4.6yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de ARVN se considera experimentada (4.5 años de antigüedad promedio).

Arvinas Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Arvinas, Inc. Appoints Randy Teel as Chief Business Officer

Arvinas, Inc., Annual General Meeting, May 29, 2024

Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. Announces Appointment of Jared Freedberg as General Counsel

Recent updates

Consensus revenue estimates increase by 17%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Arvinas, Inc. Appoints Randy Teel as Chief Business Officer

Arvinas, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates upgraded to US$5.13 loss

Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee

Arvinas: Behind The Huge Rally

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$5.76 loss

Arvinas, Inc. announced that it has received $349.999871 million in funding from a group of investors

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. and Pfizer Inc. Announces That the U.S. Food and Drug Administration Has Granted Fast Track Designation for the Investigation of Vepdegestrant (Arv-471) for Monotherapy

Arvinas, Inc. Announces Appointment of Jared Freedberg as General Counsel

Arvinas, Inc. and Pfizer Inc. Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®?) and Plans to Expand Vepdegestrant Development Program

Price target decreased by 7.5% to US$55.82

New minor risk - Share price stability

Consensus estimates of losses per share improve by 13%

Price target decreased by 7.6% to US$55.80

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 10.0% to US$60.38

Arvinas, Inc. Announces the Presentation of Interim Data from the its Phase 1/2 Clinical Trial for Bavdegalutamide

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

Consensus revenue estimates increase by 17%

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

New minor risk - Share price stability

Arvinas, Inc. Announces Changes to its Board of Directors

Arvinas, Inc. Announces Interim Data from Phase 1/2 Dose Escalation and Expansion Trial of ARV-766

Consensus revenue estimates increase by 10%, EPS downgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

Consensus EPS estimates fall by 12%

Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arvinas Announces Changes to Its Board of Directors

Arvinas, Inc. Announces in Post-Hoc Analysis from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Expects VERITAC-2 Phase 3 Trial Population Achieve Clinical Benefit Rate of 62.5%

Price target decreased to US$83.90

Arvinas, Inc. Announces Initial Results from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Co-Developed with Pfizer Inc

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Arvinas, Inc. Appoints Paul McInulty as Senior Vice President, Regulatory Affairs

Arvinas initiated Overweight at Barclays on attractive therapeutic platform

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Arvinas, Inc. Announces Changes to its Board of Directors

Chief Medical Officer exercised options and sold US$69k worth of stock

Arvinas, Inc. Appoints Lisa Sinclair as Senior Vice President, Corporate Operations

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arvinas, Inc. Appoints John Northcott as Chief Commercial Officer

Arvinas: Still Holding, Just Not Buying More

Consensus EPS estimates fall by 12%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

CFO & Treasurer exercised options and sold US$810k worth of stock

Chief Scientific Officer exercised options to buy US$226k worth of stock.

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Chief Scientific Officer notifies of intention to sell stock

Arvinas, Inc. Announces Completed Phase 1 and Interim Phase 2 ARDENT Data for Bavdegalutamide (ARV-110), A Novel PROTAC® Degrader Targeting the Androgen Receptor

Arvinas, Inc. Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 Ardent Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to Present At 2022 ASCO GU Meeting

Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma

Independent Director exercised options and sold US$793k worth of stock

Chief Medical Officer exercised options and sold US$782k worth of stock

CFO & Treasurer notifies of intention to sell stock